@article{HaberstumpfForsterLeinweberetal.2022,
  author    = {Haberstumpf, Sophia and Forster, Andr{\´e} and Leinweber, Jonas and Rauskolb, Stefanie and Hewig, Johannes and Sendtner, Michael and Lauer, Martin and Polak, Thomas and Deckert, J{\"u}rgen and Herrmann, Martin J.},
  title     = {Measurement invariance testing of longitudinal neuropsychiatric test scores distinguishes pathological from normative cognitive decline and highlights its potential in early detection research},
  series = {Journal of Neuropsychology},
  volume    = {16},
  journal   = {Journal of Neuropsychology},
  number    = {2},
  doi       = {10.1111/jnp.12269},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-318932},
  pages     = {324 -- 352},
  year      = {2022},
  abstract  = {Objective Alzheimer's disease (AD) is a growing challenge worldwide, which is why the search for early-onset predictors must be focused as soon as possible. Longitudinal studies that investigate courses of neuropsychological and other variables screen for such predictors correlated to mild cognitive impairment (MCI). However, one often neglected issue in analyses of such studies is measurement invariance (MI), which is often assumed but not tested for. This study uses the absence of MI (non-MI) and latent factor scores instead of composite variables to assess properties of cognitive domains, compensation mechanisms, and their predictability to establish a method for a more comprehensive understanding of pathological cognitive decline. Methods An exploratory factor analysis (EFA) and a set of increasingly restricted confirmatory factor analyses (CFAs) were conducted to find latent factors, compared them with the composite approach, and to test for longitudinal (partial-)MI in a neuropsychiatric test battery, consisting of 14 test variables. A total of 330 elderly (mean age: 73.78 ± 1.52 years at baseline) were analyzed two times (3 years apart). Results EFA revealed a four-factor model representing declarative memory, attention, working memory, and visual-spatial processing. Based on CFA, an accurate model was estimated across both measurement timepoints. Partial non-MI was found for parameters such as loadings, test- and latent factor intercepts as well as latent factor variances. The latent factor approach was preferable to the composite approach. Conclusion The overall assessment of non-MI latent factors may pose a possible target for this field of research. Hence, the non-MI of variances indicated variables that are especially suited for the prediction of pathological cognitive decline, while non-MI of intercepts indicated general aging-related decline. As a result, the sole assessment of MI may help distinguish pathological from normative aging processes and additionally may reveal compensatory neuropsychological mechanisms.},
  language  = {en}
}
@article{FareedQasmiAzizetal.2022,
  author    = {Fareed, Muhammad Mazhar and Qasmi, Maryam and Aziz, Shaan and V{\"o}lker, Elisabeth and F{\"o}rster, Carola Yvette and Shityakov, Sergey},
  title     = {The role of clusterin transporter in the pathogenesis of Alzheimer's disease at the blood-brain barrier interface: a systematic review},
  series = {Biomolecules},
  volume    = {12},
  journal   = {Biomolecules},
  number    = {10},
  issn      = {2218-273X},
  doi       = {10.3390/biom12101452},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290279},
  year      = {2022},
  abstract  = {Alzheimer's disease (AD) is considered a chronic and debilitating neurological illness that is increasingly impacting older-age populations. Some proteins, including clusterin (CLU or apolipoprotein J) transporter, can be linked to AD, causing oxidative stress. Therefore, its activity can affect various functions involving complement system inactivation, lipid transport, chaperone activity, neuronal transmission, and cellular survival pathways. This transporter is known to bind to the amyloid beta (Aβ) peptide, which is the major pathogenic factor of AD. On the other hand, this transporter is also active at the blood-brain barrier (BBB), a barrier that prevents harmful substances from entering and exiting the brain. Therefore, in this review, we discuss and emphasize the role of the CLU transporter and CLU-linked molecular mechanisms at the BBB interface in the pathogenesis of AD.},
  language  = {en}
}
@article{FoersterShityakovScheperetal.2022,
  author    = {F{\"o}rster, Carola Y. and Shityakov, Sergey and Scheper, Verena and Lenarz, Thomas},
  title     = {Linking cerebrovascular dysfunction to age-related hearing loss and Alzheimer's disease — are systemic approaches for diagnosis and therapy required?},
  series = {Biomolecules},
  volume    = {12},
  journal   = {Biomolecules},
  number    = {11},
  issn      = {2218-273X},
  doi       = {10.3390/biom12111717},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-297552},
  year      = {2022},
  abstract  = {Alzheimer's disease (AD), the most common cause of dementia in the elderly, is a neurodegenerative disorder associated with neurovascular dysfunction, cognitive decline, and the accumulation of amyloid β peptide (Aβ) in the brain and tau-related lesions in neurons termed neurofibrillary tangles (NFTs). Aβ deposits and NFT formation are the central pathological hallmarks in AD brains, and the majority of AD cases have been shown to exhibit a complex combination of systemic comorbidities. While AD is the foremost common cause of dementia in the elderly, age-related hearing loss (ARHL) is the most predominant sensory deficit in the elderly. During aging, chronic inflammation and resulting endothelial dysfunction have been described and might be key contributors to AD; we discuss an intriguing possible link between inner ear strial microvascular pathology and blood-brain barrier pathology and present ARHL as a potentially modifiable and treatable risk factor for AD development. We present compelling evidence that ARHL might well be seen as an important risk factor in AD development: progressive hearing impairment, leading to social isolation, and its comorbidities, such as frailty, falls, and late-onset depression, link ARHL with cognitive decline and increased risk of dementia, rendering it tempting to speculate that ARHL might be a potential common molecular and pathological trigger for AD. Additionally, one could speculate that amyloid-beta might damage the blood-labyrinth barrier as it does to the blood-brain barrier, leading to ARHL pathology. Finally, there are options for the treatment of ARHL by targeted neurotrophic factor supplementation to the cochlea to improve cognitive outcomes; they can also prevent AD development and AD-related comorbidity in the future.},
  language  = {en}
}
@article{GentzschChenSpatzetal.2021,
  author    = {Gentzsch, Christian and Chen, Xinyu and Spatz, Philipp and Košak, Urban and Knez, Damijan and Nose, Naoko and Gobec, Stanislav and Higuchi, Takahiro and Decker, Michael},
  title     = {Synthesis and Initial Characterization of a Reversible, Selective \(^{18}\)F-Labeled Radiotracer for Human Butyrylcholinesterase},
  series = {Molecular Imaging and Biology},
  volume    = {23},
  journal   = {Molecular Imaging and Biology},
  number    = {4},
  issn      = {1860-2002},
  doi       = {10.1007/s11307-021-01584-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-269870},
  pages     = {505-515},
  year      = {2021},
  abstract  = {Purpose A neuropathological hallmark of Alzheimer's disease (AD) is the presence of amyloid-β (Aβ) plaques in the brain, which are observed in a significant number of cognitively normal, older adults as well. In AD, butyrylcholinesterase (BChE) becomes associated with A\(_{β}\) aggregates, making it a promising target for imaging probes to support diagnosis of AD. In this study, we present the synthesis, radiochemistry, in vitro and preliminary ex and in vivo investigations of a selective, reversible BChE inhibitor as PET-tracer for evaluation as an AD diagnostic. Procedures Radiolabeling of the inhibitor was achieved by fluorination of a respective tosylated precursor using K[\(^{18}\)F]. IC\(_{50}\) values of the fluorinated compound were obtained in a colorimetric assay using recombinant, human (h) BChE. Dissociation constants were determined by measuring hBChE activity in the presence of different concentrations of inhibitor. Results Radiofluorination of the tosylate precursor gave the desired radiotracer in an average radiochemical yield of 20 ± 3 \%. Identity and > 95.5 \% radiochemical purity were confirmed by HPLC and TLC autoradiography. The inhibitory potency determined in Ellman's assay gave an IC\(_{50}\) value of 118.3 ± 19.6 nM. Dissociation constants measured in kinetic experiments revealed lower affinity of the inhibitor for binding to the acylated enzyme (K2 = 68.0 nM) in comparison to the free enzyme (K\(_{1}\) = 32.9 nM). Conclusions The reversibly acting, selective radiotracer is synthetically easily accessible and retains promising activity and binding potential on hBChE. Radiosynthesis with \(^{18}\)F labeling of tosylates was feasible in a reasonable time frame and good radiochemical yield.},
  language  = {en}
}
@article{RiedererterMeulen2020,
  author    = {Riederer, Peter and ter Meulen, Volker},
  title     = {Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses},
  series = {Journal of Neural Transmission},
  volume    = {127},
  journal   = {Journal of Neural Transmission},
  number    = {9},
  issn      = {0300-9564},
  doi       = {10.1007/s00702-020-02230-x},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-314637},
  pages     = {1217-1228},
  year      = {2020},
  abstract  = {While there is abounding literature on virus-induced pathology in general and coronavirus in particular, recent evidence accumulates showing distinct and deleterious brain affection. As the respiratory tract connects to the brain without protection of the blood-brain barrier, SARS-CoV-2 might in the early invasive phase attack the cardiorespiratory centres located in the medulla/pons areas, giving rise to disturbances of respiration and cardiac problems. Furthermore, brainstem regions are at risk to lose their functional integrity. Therefore, long-term neurological as well as psychiatric symptomatology and eventual respective disorders cannot be excluded as evidenced from influenza-A triggered post-encephalitic Parkinsonism and HIV-1 triggered AIDS-dementia complex. From the available evidences for coronavirus-induced brain pathology, this review concludes a number of unmet needs for further research strategies like human postmortem brain analyses. SARS-CoV-2 mirroring experimental animal brain studies, characterization of time-dependent and region-dependent spreading behaviours of coronaviruses, enlightening of pathological mechanisms after coronavirus infection using long-term animal models and clinical observations of patients having had COVID-19 infection are calling to develop both protective strategies and drug discoveries to avoid early and late coronavirus-induced functional brain disturbances, symptoms and eventually disorders. To fight SARS-CoV-2, it is an urgent need to enforce clinical, molecular biological, neurochemical and genetic research including brain-related studies on a worldwide harmonized basis.},
  language  = {en}
}
@article{VolpatoHolzgrabe2018,
  author    = {Volpato, Daniela and Holzgrabe, Ulrike},
  title     = {Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease},
  series = {Molecules},
  volume    = {23},
  journal   = {Molecules},
  number    = {12},
  issn      = {1420-3049},
  doi       = {10.3390/molecules23123230},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-197555},
  pages     = {3230},
  year      = {2018},
  abstract  = {The cholinergic hypothesis has been reported first being the cause of memory dysfunction in the Alzheimer's disease. Researchers around the globe have focused their attention on understanding the mechanisms of how this complicated system contributes to processes such as learning, memory, disorientation, linguistic problems, and behavioral issues in the indicated chronic neurodegenerative disease. The present review reports recent updates in hybrid molecule design as a strategy for selectively addressing multiple target proteins involved in Alzheimer's disease (AD) and the study of their therapeutic relevance. The rationale and the design of the bifunctional compounds will be discussed in order to understand their potential as tools to investigate the role of the cholinergic system in AD.},
  language  = {en}
}
@article{SunOrtegaTanetal.2018,
  author    = {Sun, Ping and Ortega, Gabriela and Tan, Yan and Hua, Qian and Riederer, Peter F. and Deckert, J{\"u}rgen and Schmitt-B{\"o}hrer, Angelika G.},
  title     = {Streptozotocin impairs proliferation and differentiation of adult hippocampal neural stem cells in vitro-correlation with alterations in the expression of proteins associated with the insulin system},
  series = {Frontiers in Aging Neuroscience},
  volume    = {10},
  journal   = {Frontiers in Aging Neuroscience},
  number    = {145},
  doi       = {10.3389/fnagi.2018.00145},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176741},
  year      = {2018},
  abstract  = {Rats intracerebroventricularily (icv) treated with streptozotocin (STZ), shown to generate an insulin resistant brain state, were used as an animal model for the sporadic form of Alzheimer's disease (sAD). Previously, we showed in an in vivo study that 3 months after STZ icv treatment hippocampal adult neurogenesis (AN) is impaired. In the present study, we examined the effects of STZ on isolated adult hippocampal neural stem cells (NSCs) using an in vitro approach. We revealed that 2.5 mM STZ inhibits the proliferation of NSCs as indicated by reduced number and size of neurospheres as well as by less BrdU-immunoreactive NSCs. Double immunofluorescence stainings of NSCs already being triggered to start with their differentiation showed that STZ primarily impairs the generation of new neurons, but not of astrocytes. For revealing mechanisms possibly involved in mediating STZ effects we analyzed expression levels of insulin/glucose system-related molecules such as the glucose transporter (GLUT) 1 and 3, the insulin receptor (IR) and the insulin-like growth factor (IGF) 1 receptor. Applying quantitative Real time-PCR (qRT-PCR) and immunofluorescence stainings we showed that STZ exerts its strongest effects on GLUT3 expression, as GLUT3 mRNA levels were found to be reduced in NSCs, and less GLUT3-immunoreactive NSCs as well as differentiating cells were detected after STZ treatment. These findings suggest that cultured NSCs are a good model for developing new strategies to treat nerve cell loss in AD and other degenerative disorders.},
  language  = {en}
}
@article{HibarAdamsJahanshadetal.2017,
  author    = {Hibar, Derrek P. and Adams, Hieab H.H. and Jahanshad, Neda and Chauhan, Ganesh and Stein, Jason L and Hofer, Edith and Renteria, Miguel E. and Bis, Joshua C. and Arias-Vasquez, Alejandro and Ikram, M. Kamran and Desrivi{\`e}res, Sylvane and Vernooij, Meike W. and Abramovic, Lucija and Alhusaini, Saud and Amin, Najaf and Andersson, Micael and Arfanakis, Konstantinos and Aribisala, Benjamin S. and Armstrong, Nicola J. and Athanasiu, Lavinia and Axelsson, Tomas and Beecham, Ashley H. and Beiser, Alexa and Bernard, Manon and Blanton, Susan H. and Bohlken, Marc M. and Boks, Marco P. and Bralten, Janita and Brickman, Adam M. and Carmichael, Owen},
  title     = {Novel genetic loci associated with hippocampal volume},
  series = {Nature Communications},
  volume    = {8},
  journal   = {Nature Communications},
  doi       = {10.1038/ncomms13624},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-182115},
  pages     = {12},
  year      = {2017},
  abstract  = {The hippocampal formation is a brain structure integrally involved in episodic memory, spatial navigation, cognition and stress responsiveness. Structural abnormalities in hippocampal volume and shape are found in several common neuropsychiatric disorders. To identify the genetic underpinnings of hippocampal structure here we perform a genome-wide association study (GWAS) of 33,536 individuals and discover six independent loci significantly associated with hippocampal volume, four of them novel. Of the novel loci, three lie within genes (ASTN2, DPP4 and MAST4) and one is found 200 kb upstream of SHH. A hippocampal subfield analysis shows that a locus within the MSRB3 gene shows evidence of a localized effect along the dentate gyrus, subiculum, CA1 and fissure. Further, we show that genetic variants associated with decreased hippocampal volume are also associated with increased risk for Alzheimer's disease (r\(_g\)=-0.155). Our findings suggest novel biological pathways through which human genetic variation influences hippocampal volume and risk for neuropsychiatric illness.},
  language  = {en}
}
@article{DeebGiordanoRossietal.2016,
  author    = {Deeb, Wissam and Giordano, James J. and Rossi, Peter J. and Mogilner, Alon Y. and Gunduz, Aysegul and Judy, Jack W. and Klassen, Bryan T. and Butson, Christopher R. and Van Horne, Craig and Deny, Damiaan and Dougherty, Darin D. and Rowell, David and Gerhardt, Greg A. and Smith, Gwenn S. and Ponce, Francisco A. and Walker, Harrison C. and Bronte-Stewart, Helen M. and Mayberg, Helen S. and Chizeck, Howard J. and Langevin, Jean-Philippe and Volkmann, Jens and Ostrem, Jill L. and Shute, Jonathan B. and Jimenez-Shahed, Joohi and Foote, Kelly D. and Wagle Shukla, Aparna and Rossi, Marvin A. and Oh, Michael and Pourfar, Michael and Rosenberg, Paul B. and Silburn, Peter A. and de Hemptine, Coralie and Starr, Philip A. and Denison, Timothy and Akbar, Umer and Grill, Warren M. and Okun, Michael S.},
  title     = {Proceedings of the Fourth Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies},
  series = {Frontiers in Integrative Neuroscience},
  volume    = {10},
  journal   = {Frontiers in Integrative Neuroscience},
  number    = {38},
  doi       = {10.3389/fnint.2016.00038},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-168493},
  year      = {2016},
  abstract  = {This paper provides an overview of current progress in the technological advances and the use of deep brain stimulation (DBS) to treat neurological and neuropsychiatric disorders, as presented by participants of the Fourth Annual DBS Think Tank, which was convened in March 2016 in conjunction with the Center for Movement Disorders and Neurorestoration at the University of Florida, Gainesveille FL, USA. The Think Tank discussions first focused on policy and advocacy in DBS research and clinical practice, formation of registries, and issues involving the use of DBS in the treatment of Tourette Syndrome. Next, advances in the use of neuroimaging and electrochemical markers to enhance DBS specificity were addressed. Updates on ongoing use and developments of DBS for the treatment of Parkinson's disease, essential tremor, Alzheimer's disease, depression, post-traumatic stress disorder, obesity, addiction were presented, and progress toward innovation(s) in closed-loop applications were discussed. Each section of these proceedings provides updates and highlights of new information as presented at this year's international Think Tank, with a view toward current and near future advancement of the field.},
  language  = {en}
}
@phdthesis{Iuhos2014,
  author    = {Iuhos, Diana-Iulia},
  title     = {Hypertonie als Risikofaktor f{\"u}r Morbus Alzheimer},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-109242},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2014},
  abstract  = {Die Demenz vom Alzheimer Typ ist eine prim{\"a}r degenerative Erkrankung des Gehirns, die heutzutage die h{\"a}ufigste Ursache f{\"u}r eine Demenzerkrankung darstellt. Sie ist pathologisch gekennzeichnet durch typische histologische fassbare zerebrale Ver{\"a}nderungen, Neurofibrillenb{\"u}ndel und amyloide Plaques, und einer ausgepr{\"a}gten, kortikal betonten Hirnatrophie gekennzeichnet. Zu den wichtigsten klinischen Leitsymptomen z{\"a}hlen Ged{\"a}chtnis- und Wortfindungsst{\"o}rungen sowie eine zeitliche und {\"o}rtliche Orientierungsst{\"o}rung. Es werden zwei Formen unterschieden: Die seltene famili{\"a}r autosomal- dominant vererbte Form mit fr{\"u}hem Beginn (Beginn vor dem 65. Lebensjahr) und die h{\"a}ufigste, die sporadische Form (Beginn nach dem 65. Lebensjahr), deren Ursache bis heute nicht vollst{\"a}ndig gekl{\"a}rt ist. Zu den wichtigsten Risikofaktoren der sAD z{\"a}hlt neben einer positiven Familienanamnese vor allem das Alter. Mittlerweile konnten immer mehr Studien auch ein deutlich hohes Risiko f{\"u}r AD besonders f{\"u}r Patienten mit unbehandelter Hypertonie belegen. Inzwischen mehren sich seit l{\"a}ngerer Zeit die Hinweise, dass ein wichtiger Zusammenhang zwischen der Entstehung von sAD und arterieller Hypertonie besteht. Ausgehend von der Hypothese, dass ein gest{\"o}rter zerebraler Insulinmetabolismus pathogenetisch bedeutsam f{\"u}r die Entwicklung einer sAD ist, werden in der Literatur zudem gehirnspezifische Ver{\"a}nderungen in der Insulin/ IR-Signalkaskade bei sAD beschrieben, die daraufhin deuten, dass es sich bei sAD um eine neuroendokrine St{\"o}rung handelt. Die vorliegende Studie besch{\"a}ftigt sich nun mit der Frage, ob ein Zusammenhang zwischen metabolischen Syndrom (wie arterielle Hypertonie und Insulinresistenz) und sAD nachweisbar ist und ob Hypertonie gehirnspezifische Ver{\"a}nderungen in der in der Insulin/ IR-Signalkaskade hervorrufen und somit auf diesen Weg pathophysiologischen Prozesse einer sAD f{\"o}rdern kann. Um diesen Zusammenhang zu {\"u}berpr{\"u}fen, wurden in dieser Studie erstmals Spontan Hypertensive Ratten (SHR) als experimentelles Modell ausgew{\"a}hlt. Dabei wurden Ver{\"a}nderungen bez{\"u}glich der Insulinrezeptorkonzentration sowie weiterer Bestandteile der Insulin/ IR-Signalkaskade in Gehirnen von drei Monate alten SHR und altersentsprechenden Kontrollratten mittels Enzym- Linked-Immuno-Sorbent Assays (ELISA) untersucht und miteinander verglichen. In dieser Studie war sowohl insgesamt als auch in allen untersuchten Regionen mit Ausnahme des Hypothalamus eine Erniedrigung der IRβ - Konzentration und damit ein deutlicher Mangel an IR β im Hirngewebe der SHR nachweisbar. Die Resultate des IR pTyr -fielen mit einer insgesamt tendenziellen Reduktion der IR pTyr - Konzentration der SHR {\"a}hnlich aus, wobei es innerhalb der Hirnregionen regionale Konzentrationsunterschiede gab. Bez{\"u}glich der aktivierten PKB ergab sich eine erniedrigte Gesamtkonzentration im Hirngewebe der SHR, allerdings war beim Gruppenvergleich in den einzelnen Hirnregionen nur im Hippokampus ein eindeutig signifikanter Konzentrationsunterschied zwischen beiden Gruppen zu verzeichnen. Die GSK 3β - Gesamtkonzentration der SHR zeigte sowohl insgesamt als auch in Vergleich zur Kontrollgruppe eine deutliche Erniedrigung. Im Gegensatz hierzu war die GSK- 3β pSer- Gesamtkonzentrationen der SHR insgesamt leicht erniedrigt, beim Vergleich der vier verschiedenen Hirnregionen zeigten sich jedoch keine signifikanten regionalen Konzentrationsunterschiede. Ein eindeutiger statistischer Zusammenhang zwischen den N{\"u}chtern- Blutzuckerspiegel, den Blutzuckerspiegel 30 Minuten nach Glukosetoleranztest und den jeweiligen K{\"o}rpergewicht der SHR und den Bestandteilen der Insulinrezeptorsignalkaskade konnte in der vorliegenden Studie nicht beobachtet werden. Zusammenfassend l{\"a}sst sich sagen, dass in den Gesamtproben der SHR signifikante St{\"o}rungen in der Signaltransduktion des Insulin-/ Insulinrezeptorsystem nachgewiesen werden konnten, die in der Literatur f{\"u}r sAD als typisch beschrieben werden. Dies untermauert wiederum die Hypothese, dass es sich bei der sAD um eine neuroendokrine St{\"o}rung mit gehirnspezifischen Fehlfunktionen in der Insulinrezeptorsignalkaskade handelt. Des Weiteren l{\"a}sst diese Arbeit den Schluss zu, dass es einen m{\"o}glichen Zusammenhang zwischen metabolischem Syndrom (wie arterielle Hypertonie und Insulinresistenz) und sAD gibt und Hypertonie ein bedeutsamer Risikofaktor f{\"u}r die Entwicklung einer sAD sein kann. Eine direkte Verbindung zwischen beiden Erkrankungen konnte jedoch nicht nachgewiesen werden. Weiterf{\"u}hrende und erg{\"a}nzende Untersuchungen mit zum Beispiel {\"a}lteren SHR und zus{\"a}tzlichen histopathologsichen Untersuchung werden jedoch notwendig sein, um diese Aussage zu best{\"a}tigen.  },
  subject      = {Morbus Alzheimer},
  language  = {de}
}
@article{BoltzeKleinschnitzReymannetal.2012,
  author    = {Boltze, Johannes and Kleinschnitz, Christoph and Reymann, Klaus G. and Reiser, Georg and Wagner, Daniel-Christoph and Kranz, Alexander and Michalski, Dominik},
  title     = {Neurovascular pathophysiology in cerebral ischemia, dementia and the ageing brain - current trends in basic, translational and clinical research},
  series = {Experimental \& Translational Stroke Medicine},
  volume    = {4},
  journal   = {Experimental \& Translational Stroke Medicine},
  number    = {14},
  doi       = {doi:10.1186/2040-7378-4-14},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126679},
  year      = {2012},
  abstract  = {The 7th International Symposium on Neuroprotection and Neurorepair was held from May 2nd to May 5th, 2012 in Potsdam, Germany. The symposium, which directly continues the successful Magdeburg meeting series, attracted over 330 colleagues from 29 countries to discuss recent findings and advances in the field. The focus of the 2012 symposium was widened from stroke and traumatic brain injury to neurodegenerative diseases, notably dementia, and more generally the ageing brain. Thereby, emphasis was given on neurovascular aspects of neurodegeneration and stroke including the blood-brain barrier, recent findings regarding the pathomechanism of Alzheimer's disease, and brain imaging approaches. In addition, neurobiochemical aspects of neuroprotection, the role of astrogliosis, the clinical progress of cell-based approaches as well as translational hurdles and opportunities were discussed in-depth. This review summarizes some of the most stimulating discussions and reports from the meeting.},
  language  = {en}
}